166 related articles for article (PubMed ID: 28787411)
21. Successful treatment with gilteritinib for initially FMS-like tyrosine kinase 3 gene internal tandem duplications-positive elderly refractory acute myeloid leukemia that changed into FMS-like tyrosine kinase 3 gene tyrosine kinase domain-positive after cord blood transplantation.
Akahane D; Moriyama M; Yoshizawa S; Katagiri S; Fujimoto H; Gotoh A
Geriatr Gerontol Int; 2019 Oct; 19(10):1063-1064. PubMed ID: 31602758
[No Abstract] [Full Text] [Related]
22. Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.
Tallman M
Clin Adv Hematol Oncol; 2008 Nov; 6(11):3-5. PubMed ID: 19205108
[No Abstract] [Full Text] [Related]
23. Acute leukemias in 2020: state of the art.
Cerchione C; Martinelli G
Minerva Med; 2020 Oct; 111(5):384-385. PubMed ID: 32957743
[No Abstract] [Full Text] [Related]
24. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
Garcia JS; Percival ME
Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
[TBL] [Abstract][Full Text] [Related]
25. A case report of combined treatment of gilteritinib and LH-RH agonist for Fms-related tyrosine kinase 3 receptor mutation-positive acute myeloid leukemia and bone marrow metastasis of prostate cancer.
Onaka T; Kato-Ogura A; Otsuka Y; Iwai F; Yonezawa A
Ann Hematol; 2022 Feb; 101(2):457-458. PubMed ID: 33846854
[No Abstract] [Full Text] [Related]
26. Management of Midostaurin-CYP3A4 Drug-Drug Interactions in Patients With Acute Myeloid Leukemia.
Schlafer D
Oncology (Williston Park); 2019 Jul; 33(7):. PubMed ID: 31365750
[No Abstract] [Full Text] [Related]
27. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.
Albers C; Leischner H; Verbeek M; Yu C; Illert AL; Peschel C; von Bubnoff N; Duyster J
Leukemia; 2013 Jun; 27(6):1416-8. PubMed ID: 23392356
[No Abstract] [Full Text] [Related]
28. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.
Swords R; Freeman C; Giles F
Leukemia; 2012 Oct; 26(10):2176-85. PubMed ID: 22614177
[TBL] [Abstract][Full Text] [Related]
29. First Approved Kinase Inhibitor for AML.
Rasko JEJ; Hughes TP
Cell; 2017 Nov; 171(5):981. PubMed ID: 29149610
[TBL] [Abstract][Full Text] [Related]
30. Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial.
Zeidan AM; Qi CZ; Yang H; Garnham A; Shah MV; Pandya BJ
Leuk Lymphoma; 2022 Mar; 63(3):762-764. PubMed ID: 34749571
[No Abstract] [Full Text] [Related]
31. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Kayser S; Levis MJ; Schlenk RF
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
[TBL] [Abstract][Full Text] [Related]
32. Midostaurin in FLT3-mutated acute myeloid leukaemia.
Das M
Lancet Oncol; 2017 Aug; 18(8):e439. PubMed ID: 28669736
[No Abstract] [Full Text] [Related]
33. Preliminary data on ASP2215: tolerability and efficacy in acute myeloid leukemia patients.
Thom C
Future Oncol; 2015 Sep; 11(18):2499-501. PubMed ID: 26279055
[TBL] [Abstract][Full Text] [Related]
34. Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
Percival MM; Estey EH
Cancer; 2019 Sep; 125(18):3121-3130. PubMed ID: 31291012
[TBL] [Abstract][Full Text] [Related]
35. New drugs in acute myeloid leukemia.
Estey E
Semin Oncol; 2008 Aug; 35(4):439-48. PubMed ID: 18692694
[TBL] [Abstract][Full Text] [Related]
36. New agents: great expectations not realized.
Lancet JE
Best Pract Res Clin Haematol; 2013 Sep; 26(3):269-74. PubMed ID: 24309529
[TBL] [Abstract][Full Text] [Related]
37. Can FLT3 inhibitors overcome resistance in AML?
Tam WF; Gary Gilliland D
Best Pract Res Clin Haematol; 2008 Mar; 21(1):13-20. PubMed ID: 18342808
[TBL] [Abstract][Full Text] [Related]
38. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.
Lee LY; Hernandez D; Rajkhowa T; Smith SC; Raman JR; Nguyen B; Small D; Levis M
Blood; 2017 Jan; 129(2):257-260. PubMed ID: 27908881
[No Abstract] [Full Text] [Related]
39. Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin.
Chevallier P; Prebet T; Pigneux A; Hunault M; Delaunay J; Perry F; Lode L; Richebourg S; Blanchet O; Vey N; Ifrah N; Milpied N; Blaise D; Harousseau JL; Mohty M
Leukemia; 2010 Feb; 24(2):467-9. PubMed ID: 19847200
[No Abstract] [Full Text] [Related]
40. Pediatric acute myeloid leukemia co-expressing FLT3/ITD and NUP98/NSD1 treated with gilteritinib plus allogenic peripheral blood stem cell transplantation: A case report.
Abematsu T; Nishikawa T; Shiba N; Iijima-Yamashita Y; Inaba Y; Takahashi Y; Nakagawa S; Kodama Y; Okamoto Y; Kawano Y
Pediatr Blood Cancer; 2021 Nov; 68(11):e29216. PubMed ID: 34245496
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]